InSights Hub

News

Showing 141 to 150 of 283 (Page 15)

Dapagliflozin (Farxiga/AZ) – Guidelines+ Monographs (August 2024 Edition)

In this edition of our Guidelines Monographs Series, we will be taking a look at AstraZeneca’s medication dapagliflozin, brand name Farxiga. Initially approved in 2014, Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, provided to individuals with diabetes, heart disease, or kidney disease to improve their outcomes. This Guidelines+ Monograph will take a deeper dive […]

Read More
Guidelines+ Trials Spotlight - ITRAILBLAZER-ALZ 2

TRAILBLAZER-ALZ 2 Topline Results for the Treatment of Alzheimer’s Disease – Guidelines+ Trials Spotlight

On July 2, 2024, the US Food and Drug Administration (FDA) granted approval for Eli Lilly’s Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. This treatment is recommended for patients in the early stages of the disease, specifically those with mild cognitive impairment or mild dementia, as demonstrated in the clinical trials. Kisunla marks […]

Read More
Guidelines Spotlight Immunization Schedules for Adults and Children

Immunization Schedules for Adults and Children – Guidelines Spotlight (National Immunization Awareness Month)

As we prepare for the National Immunization Awareness Month 2024 and upcoming autumn season, we will be conducting a thorough review of the United States Immunization Schedules for both Adults and Children. These crucial recommendations are released annually by the Centers for Disease Control and Prevention (CDC). They offer essential guidance on the recommended schedules […]

Read More
Healthcare News & Research - August 2024

Healthcare News & Research – August 2024

Welcome to our succinct summaries of the most recent healthcare news and research. Keep yourself informed with our easily digestible updates sourced from medical media and news outlets. Aspirin Use and Incidence of Colorectal Cancer According to Lifestyle Risk Study Details | Source Impact of Inflammation on Cognitive Function in Patients With Highly Inflammatory Rheumatoid Arthritis […]

Read More

AAN’s Migraine Prevention Guideline is Now Open for Public Comment

The American Academy of Neurology (AAN) has announced that their latest guideline, “Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Update: Report of the AAN Guidelines Subcommittee,” is now open for public comment. This practice guideline offers updated evidence-based conclusions and recommendations on the use of pharmacologic migraine prevention in adults. The primary objective […]

Read More
Guidelines Rundown - Breastfeeding

Breastfeeding – Guidelines Rundown (National Breastfeeding Month 2024)

Our Guidelines Rundown Series continues with a new article that delves into the topic of breastfeeding in support of National Breastfeeding Month 2024. To provide guidance and clinical decision-making support on the matter, the Academy of Breastfeeding Medicine has published a comprehensive set of guidelines that address various aspects of breastfeeding, such as nutrition, supplements, […]

Read More
Upcoming FDA Approvals & Decisions

Upcoming FDA Decisions – August 2024

The Food and Drug Administration (FDA) protects public health by guaranteeing the safety, effectiveness, and security of pharmaceuticals and medical devices. The Prescription Drug User Fee Act (PDUFA) date marks the deadline by which the FDA must complete its review of drug applications. Occasionally, an advisory committee (AdCom) meeting is convened to assess the drug […]

Read More
WHO Int'l Guidelines

The World Health Organization (WHO) – Guidelines International Series

In the latest installment of our Guidelines International Series, we will be delving into the latest guidelines from the World Health Organization (WHO). Established in 1948, WHO is a specialized agency of the United Nations (UN) that facilitates collaboration between nations, partners, and individuals to advance global health, ensure global security, and support marginalized populations. […]

Read More
« Back to InSights Hub